Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
A1c Test Archives
Print | Email | Share | Comments (0)

New Drug Shows Exenatide-Like Promise in Type 2 Treatment

Oct 13, 2008

The Novo Nordisk-funded study study also tracked weight: in the first 16 weeks, the subjects taking liraglutide lost weight, while most of those taking glimepiride gained weight.

An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.

Liraglutide is a manmade analog of the hormone GLP-1 (glucagon-like peptide-1), which stimulates the growth of insulin-producing beta cells in the pancreas and insulin secretion.

Because of liraglutide's success in the phase 3 trial, its manufacturer, Novo Nordisk, will now seek approval from  the Food and Drug Administration to market liraglutide in the United States.

In the one-year Novo Nordisk-funded study conducted by the Baylor College of Medicine in Houston, 746 type 2 patients received once daily injections of either 1.2 mg or 1.8 mg of liraglutide or a once daily oral tablet of glimepiride, a sulfonylurea that promotes insulin production.
Patients receiving liraglutide also took dummy pills, while patients taking glimepiride also received dummy injections.

As they began treatment, patients' A1c's ranged from 7% to 11%. By the end of the study:

  • the A1c's of patients receiving 1.8 mg of liraglutide daily dropped by 1.14 percent
  • the A1c's of patients receiving 1.2 mg of liraglutide daily dropped by 0.84 percent
  • the A1c's of patients taking glimepiride daily dropped by 0.51 percent

Six patients had to drop out of the study due to severe nausea. Common side effect of exenatide-like drugs are. nausea, diarrhea, and vomiting, symptoms that ease up or disappear within 30 days in most patients.

The study also tracked weight: in the first 16 weeks, the subjects taking liraglutide lost weight, while most of those taking glimepiride gained weight. 


Categories: A1c Test, Food, Insulin, Medications Research, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Oct 13, 2008

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.